|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TXNL1 |
Gene summary for TXNL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TXNL1 | Gene ID | 9352 |
| Gene name | thioredoxin like 1 | |
| Gene Alias | HEL-S-114 | |
| Cytomap | 18q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000502 | UniProtAcc | O43396 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9352 | TXNL1 | SYSMH5 | Human | Oral cavity | OSCC | 1.13e-04 | 3.91e-01 | 0.0647 |
| 9352 | TXNL1 | SYSMH6 | Human | Oral cavity | OSCC | 2.89e-20 | 6.44e-01 | 0.1275 |
| 9352 | TXNL1 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 2.77e-13 | 6.06e-01 | -0.1972 |
| 9352 | TXNL1 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 1.59e-02 | 3.29e-01 | -0.2126 |
| 9352 | TXNL1 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 1.85e-05 | 6.56e-01 | -0.2247 |
| 9352 | TXNL1 | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 2.17e-02 | 7.33e-01 | -0.2027 |
| 9352 | TXNL1 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 7.77e-13 | 6.86e-01 | -0.1833 |
| 9352 | TXNL1 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 1.31e-03 | 5.37e-01 | -0.23 |
| 9352 | TXNL1 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 3.17e-08 | 6.77e-01 | -0.23 |
| 9352 | TXNL1 | 047563_1562-all-cells | Human | Prostate | BPH | 1.59e-17 | -1.06e-01 | 0.0791 |
| 9352 | TXNL1 | Dong_P1 | Human | Prostate | Tumor | 2.48e-17 | 3.81e-02 | 0.035 |
| 9352 | TXNL1 | Dong_P3 | Human | Prostate | Tumor | 4.34e-07 | 1.29e-02 | 0.0278 |
| 9352 | TXNL1 | Dong_P4 | Human | Prostate | Tumor | 3.33e-05 | 1.27e-01 | 0.0292 |
| 9352 | TXNL1 | Dong_P5 | Human | Prostate | Tumor | 9.68e-23 | -4.55e-02 | 0.053 |
| 9352 | TXNL1 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 1.17e-07 | 1.66e-01 | 0.1557 |
| 9352 | TXNL1 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.59e-03 | 4.29e-02 | 0.1602 |
| 9352 | TXNL1 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 5.11e-03 | -1.24e-01 | 0.1575 |
| 9352 | TXNL1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 4.94e-16 | -1.70e-01 | 0.1545 |
| 9352 | TXNL1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 4.97e-08 | -1.59e-01 | 0.1569 |
| 9352 | TXNL1 | P4_S8_cSCC | Human | Skin | cSCC | 3.35e-13 | 2.02e-01 | -0.3095 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TXNL1 | SNV | Missense_Mutation | novel | c.484N>A | p.Asp162Asn | p.D162N | O43396 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TXNL1 | SNV | Missense_Mutation | c.659N>C | p.Leu220Pro | p.L220P | O43396 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TXNL1 | SNV | Missense_Mutation | c.585A>C | p.Lys195Asn | p.K195N | O43396 | protein_coding | deleterious(0) | possibly_damaging(0.814) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| TXNL1 | SNV | Missense_Mutation | novel | c.93N>A | p.Met31Ile | p.M31I | O43396 | protein_coding | tolerated(0.05) | benign(0.001) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TXNL1 | SNV | Missense_Mutation | novel | c.839N>A | p.Arg280Gln | p.R280Q | O43396 | protein_coding | deleterious(0) | possibly_damaging(0.848) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TXNL1 | SNV | Missense_Mutation | c.585N>C | p.Lys195Asn | p.K195N | O43396 | protein_coding | deleterious(0) | possibly_damaging(0.814) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| TXNL1 | SNV | Missense_Mutation | rs745346344 | c.479N>G | p.Asp160Gly | p.D160G | O43396 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TXNL1 | SNV | Missense_Mutation | c.700N>T | p.Arg234Cys | p.R234C | O43396 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TXNL1 | deletion | Frame_Shift_Del | novel | c.482delG | p.Cys161LeufsTer20 | p.C161Lfs*20 | O43396 | protein_coding | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| TXNL1 | deletion | Frame_Shift_Del | c.855delA | p.Gly286GlufsTer23 | p.G286Efs*23 | O43396 | protein_coding | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |